Efficacy & Long-term Safety Comparison Study of NK-104-CR & Livalo® IR With Primary Hyperlipidemia or Mixed Dyslipidemia
Status:
Withdrawn
Trial end date:
2017-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate the superior efficacy of NK-104-CR 8 mg daily
compared to Livalo® IR 4 mg daily on fasting serum low-density lipoprotein cholesterol
(LDL-C) reduction and to evaluate the comparative safety of NK-104-CR 8 mg daily to Livalo®
IR 4 mg daily after long-term treatment